Clinical trial
A Safety and Effectiveness Study of Aroplatin in Patients With Advanced…
NCT00043199 · Aronex Pharmaceuticals, Industry · Unknown status
Key facts
| NCT number | NCT00043199 |
|---|---|
| Title | A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Colorectal Cancer Resistant to Standard Therapies |
| Official title | A Phase II Study of Aroplatin in Subjects With Recurrent, Unresectable and Metastatic Colorectal Cancer Refractory to 5-Fluorouracil (5-FU)/Leucovorin or Capecitabine, and Irinotecan |
| Lead sponsor | Aronex Pharmaceuticals, Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Neoplasms |
| Intervention type | Drug |
| Interventions | Aroplatin (Liposomal NDDP, L-NDDP) |
| Enrollment | 40 |
| First posted | Aug 8, 2002 |
| Last update posted | Jun 24, 2005 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: